SALT LAKE CITY, April 19, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said results from a recent study indicate that expression of the PTEN gene may be clinically useful in assessing a man’s risk of prostate cancer recurrence after radical prostatectomy.
